<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643901</url>
  </required_header>
  <id_info>
    <org_study_id>Tmab-GW003-NP-03</org_study_id>
    <nct_id>NCT02643901</nct_id>
  </id_info>
  <brief_title>Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects</brief_title>
  <official_title>The Single-Dose Tolerability and PK/PD Study of Recombinant (Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu T-Mab Biopharma Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu T-Mab Biopharma Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to access the tolerability and Pharmacokinetic/Pharmacodynamic (PK/PD)
      of single subcutaneous (SC) injection of GW003 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">October 10, 2016</completion_date>
  <primary_completion_date type="Actual">October 10, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to day 21</time_frame>
    <description>To evaluate the safety and tolerance of single SC injection of GW003 in healthy subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of subjects with Anti-GW003 antibody</measure>
    <time_frame>up to 6 months after the trial</time_frame>
    <description>anti-GW003 was detected pre-dose and at the last visit,if there exist positive anti-GW003 antibody, another detected should be conducted 6 months after the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life(consist of distribution and elimination half-life) for GW003</measure>
    <time_frame>up to day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the concentration-time curve(AUC) for GW003</measure>
    <time_frame>up to day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Chemotherapy-induced Neutropenia</condition>
  <arm_group>
    <arm_group_label>Ic-GW003 150ug/kg 4-8subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine:GW003 freeze-dried powder single SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ic-GW003 300ug/kg 6-8subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine:GW003 freeze-dried powder single SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ic-GW003 500ug/kg 6-8subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine:GW003 freeze-dried powder single SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ic-GW003 650ug/kg 6-8subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine:GW003 freeze-dried powder single SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ic-GW003 850ug/kg 6-8subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine:GW003 freeze-dried powder single SC injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GW003</intervention_name>
    <description>single SC injection</description>
    <arm_group_label>Ic-GW003 150ug/kg 4-8subjects</arm_group_label>
    <arm_group_label>Ic-GW003 300ug/kg 6-8subjects</arm_group_label>
    <arm_group_label>Ic-GW003 500ug/kg 6-8subjects</arm_group_label>
    <arm_group_label>Ic-GW003 650ug/kg 6-8subjects</arm_group_label>
    <arm_group_label>Ic-GW003 850ug/kg 6-8subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years to 45 years,Healthy male and female subjects.in the same dose group,the age
             difference between in 10 years

          -  At least 50kg weight,BMI between 19 and 25kg/m2

          -  No tobacco, alcohol and other bad habits

          -  No history of drug allergy and biological agents allergy and other allergies

          -  Not used biological agents and other drugs within three months before participated in
             this test

          -  Not participated in other test or donated blood within three months before
             participated in this test

          -  The medical history、physical examination、laboratory examination is normal or slightly
             abnormal

          -  Subjects can obey the clinical trial protocol

          -  Subjects, who are willing to follow the study protocol and provide written informed
             consent voluntarily.

        Exclusion Criteria:

          -  History of severe system disease(especially with the spleen swelling, adult
             respiratory distress syndrome and exudative pneumonia or sickle red blood cell anemia
             history)

          -  History of drug allergy and biological agents allergy and other allergies

          -  Subjects have used any long discharge period drugs will affect the present study
             within 3 months or are using drugs now

          -  Subjects not to take effective contraceptive measures or have a family planning within
             one year， Pregnancy or nursing women

          -  Subjects accepted major surgery 4 weeks before drug administration

          -  Subjects vaccinated live vaccine 3 months before drug administration

          -  Subjects with the history of drug abuse 5 years before drug administration

          -  As the subjects participated 3 times or more than 3 times drug clinical trials within
             1 year or as the subjects participated any drug clinical trial or donated blood within
             3 months

          -  Clinical and laboratory examination results is abnormal and have clinical significance

          -  Subjects with poor compliance or have any unfavorable factors to participate in this
             test

          -  Subjects can not complete the research

          -  The researchers and their family members.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi Junyuan, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Hematonosis Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin Hematonosis Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>30020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

